Shots:
- Formycon has entered into an exclusive licensing & supply agreement with Zydus Lifesciences Global FZE, UAE (Zydus‘ subsidiary) to commercialize Formycon’s FYB206, a biosimilar version of Merck’s Keytruda (pembrolizumab), in the US & Canada
- As per the deal, Formycon will be responsible for development, registration, manufacturing & supply of the product, while Zydus Lifesciences Global FZE, UAE will handle its commercialization in the licensed territories
- FYB206 is a humanized monoclonal antibody targeting PD-1 receptors, & its BLA application is expected to be submitted to the US FDA in the near future
Ref: PRnewswire | Image: Formycon & Zydus |Press Release
Related News: Formycon Partners with MS Pharma to Commercialize FYB206 (Biosimilar, Keytruda) in the MENA Region
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
